Scientific publications Archivi

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

D’Alise et al, 2026 Nature Medicine Published

Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model

Secli et al, Nous-PEV neoadjuvant, JITC Nov 2025

NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

De Marco et al, Mol Cancer Ther, 2025

Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine

Garzia I et al, Cancer Immunol Res. 2024

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

D’Alise et al, Clin Cancer Res 2024

Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer

The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing [...]

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

D’Alise AM et al, Front Immunol. 2023

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

Seclì et al, J Immunother Cancer. 2023

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy

D’Alise AM, Scarselli E. Curr Opin Oncol. 2023 Mar

Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection

D’Alise AM et al. Sci Transl Med 2022